RP5063
RVP-20-001
Phase 2 small_molecule completed
Quick answer
RP5063 for Acute Schizophrenia is a Phase 2 program (small_molecule) at REVIVA PHARMACEUTICALS HOLDINGS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- REVIVA PHARMACEUTICALS HOLDINGS, INC.
- Indication
- Acute Schizophrenia
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed